Description
Telios Pharma A Phase 2 Multicenter Study of TL-895 in Subjects with Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Activation Syndrome clinical trial
Study details
For detailed information on this trial, please click here
Trial status
Oxford now open
Location
Principal Investigator
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.